rasagiline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoamine oxydase (MAO)-inhibitors type B 3521 136236-51-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • TVP-1022
  • rasagiline hydrochloride
  • rasagiline
  • azilect
  • (R)-(+)-Rasagiline
  • rasagiline mesylate
  • TV-1030
  • rasagiline mesilate
Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of rasagiline tablets on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of rasagiline tablets. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline’s beneficial effects seen in models of dopaminergic motor dysfunction.
  • Molecular weight: 171.24
  • Formula: C12H13N
  • CLOGP: 2.34
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -3.84
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 36 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 20 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK 41
kinase-selectivity-class AXL,BRAF,PDK4 3
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
March 23, 2018 PMDA Takeda Pharmaceutical Company Limited
May 16, 2006 FDA TEVA
Feb. 21, 2005 EMA TEVA B.V.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 337.44 22.66 117 6036 36417 90585877
Hallucination 310.27 22.66 129 6024 65830 90556464
Hallucination, visual 232.72 22.66 79 6074 23013 90599281
On and off phenomenon 172.68 22.66 39 6114 2504 90619790
Fall 161.44 22.66 180 5973 481630 90140664
Serotonin syndrome 160.90 22.66 69 6084 37818 90584476
Freezing phenomenon 118.75 22.66 27 6126 1785 90620509
Tremor 98.15 22.66 82 6071 153091 90469203
Orthostatic hypotension 90.73 22.66 48 6105 41779 90580515
Drug interaction 88.30 22.66 101 6052 276352 90345942
Bradykinesia 83.42 22.66 27 6126 6761 90615533
Delusion 81.91 22.66 32 6121 13808 90608486
Stoma site discharge 75.15 22.66 19 6134 1970 90620324
Muscle rigidity 73.94 22.66 30 6123 14279 90608015
Pleurothotonus 72.09 22.66 17 6136 1318 90620976
Gambling disorder 57.56 22.66 14 6139 1238 90621056
Sudden onset of sleep 56.58 22.66 12 6141 573 90621721
Dystonia 56.45 22.66 26 6127 16793 90605501
Stoma site erythema 55.08 22.66 14 6139 1482 90620812
Akinesia 53.02 22.66 14 6139 1722 90620572
Impulse-control disorder 50.39 22.66 12 6141 970 90621324
Confusional state 43.87 22.66 87 6066 386118 90236176
Dopamine dysregulation syndrome 43.63 22.66 8 6145 178 90622116
Stoma site hypergranulation 42.98 22.66 9 6144 404 90621890
Compulsive shopping 42.61 22.66 10 6143 759 90621535
Anxiety 41.63 22.66 75 6078 309697 90312597
Altered state of consciousness 41.11 22.66 26 6127 31506 90590788
Agitation 41.00 22.66 35 6118 67063 90555231
Hypersexuality 39.25 22.66 9 6144 617 90621677
Balance disorder 38.81 22.66 40 6113 97040 90525254
Fracture 38.63 22.66 22 6131 22054 90600240
Labelled drug-drug interaction medication error 38.15 22.66 19 6134 14563 90607731
Dementia 37.04 22.66 22 6131 23839 90598455
Colitis microscopic 36.66 22.66 17 6136 11142 90611152
Serum serotonin increased 36.01 22.66 7 6146 215 90622079
Stoma site infection 35.63 22.66 9 6144 929 90621365
Coronary artery dissection 35.48 22.66 9 6144 945 90621349
Gait disturbance 34.89 22.66 63 6090 260433 90361861
Device dislocation 33.82 22.66 23 6130 31459 90590835
Dysphagia 30.74 22.66 38 6115 112240 90510054
Compulsive hoarding 30.49 22.66 5 6148 56 90622238
Hip fracture 30.48 22.66 22 6131 33055 90589239
Syncope 30.23 22.66 41 6112 132622 90489672
Choking 29.49 22.66 15 6138 12018 90610276
Sleep talking 29.24 22.66 8 6145 1125 90621169
Device issue 28.03 22.66 20 6133 29517 90592777
Stoma site extravasation 27.86 22.66 6 6147 308 90621986
Psychotic symptom 27.82 22.66 9 6144 2247 90620047
Autonomic neuropathy 27.41 22.66 8 6145 1419 90620875
Presyncope 26.70 22.66 20 6133 31785 90590509
Hypertensive crisis 26.57 22.66 16 6137 17768 90604526
Cerebral atrophy 26.32 22.66 11 6142 5635 90616659
Disorientation 24.89 22.66 22 6131 44092 90578202
Abnormal dreams 24.62 22.66 13 6140 11244 90611050
Wrong device used 24.54 22.66 4 6149 43 90622251
Dizziness postural 24.29 22.66 12 6141 9041 90613253
Compulsions 24.25 22.66 5 6148 208 90622086
Autonomic nervous system imbalance 24.08 22.66 9 6144 3441 90618853
Parkinsonian gait 24.08 22.66 6 6147 586 90621708
Stoma site haemorrhage 23.51 22.66 7 6146 1331 90620963
Death 23.32 22.66 76 6077 456475 90165819
Femoral neck fracture 22.90 22.66 12 6141 10221 90612073
Nocturia 22.87 22.66 12 6141 10243 90612051
Anticoagulation drug level below therapeutic 22.82 22.66 6 6147 725 90621569

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 502.41 24.45 251 9612 57256 42554216
Dyskinesia 336.42 24.45 148 9715 25242 42586230
Impulse-control disorder 330.50 24.45 76 9787 1499 42609973
On and off phenomenon 266.41 24.45 75 9788 3392 42608080
Hypersexuality 242.14 24.45 60 9803 1642 42609830
Hallucination, visual 216.80 24.45 103 9760 20917 42590555
Gambling disorder 185.80 24.45 49 9814 1727 42609745
Fall 171.34 24.45 239 9624 234281 42377191
Cerebral hypoperfusion 159.63 24.45 39 9824 1004 42610468
Freezing phenomenon 159.45 24.45 44 9819 1845 42609627
Orthostatic hypotension 138.72 24.45 87 9776 30483 42580989
Dopamine dysregulation syndrome 127.42 24.45 29 9834 544 42610928
Confusional state 113.51 24.45 165 9698 167432 42444040
Delusion 109.92 24.45 58 9805 14676 42596796
Serotonin syndrome 105.93 24.45 69 9794 25776 42585696
Bradykinesia 89.44 24.45 37 9826 5399 42606073
Speech disorder 89.23 24.45 65 9798 29056 42582416
Gait disturbance 88.36 24.45 111 9752 97889 42513583
Abnormal behaviour 80.95 24.45 59 9804 26392 42585080
Sudden onset of sleep 71.56 24.45 17 9846 387 42611085
Muscle rigidity 69.37 24.45 40 9823 12019 42599453
Balance disorder 65.09 24.45 67 9796 47578 42563894
Resting tremor 64.98 24.45 19 9844 982 42610490
Tremor 64.83 24.45 95 9768 96834 42514638
Device dislocation 64.63 24.45 33 9830 7798 42603674
Cognitive disorder 63.62 24.45 57 9806 34115 42577357
Dystonia 62.02 24.45 38 9825 12752 42598720
Stoma site discharge 61.76 24.45 20 9843 1456 42610016
Nocturia 61.33 24.45 37 9826 12075 42599397
Binocular eye movement disorder 60.19 24.45 14 9849 290 42611182
Compulsive shopping 59.31 24.45 15 9848 446 42611026
Somnolence 57.79 24.45 111 9752 140994 42470478
Jealous delusion 55.92 24.45 14 9849 399 42611073
Embedded device 54.98 24.45 14 9849 428 42611044
Cerebellar stroke 54.50 24.45 15 9848 622 42610850
Agitation 51.87 24.45 69 9794 64245 42547227
Psychomotor hyperactivity 51.71 24.45 32 9831 10926 42600546
Feeling cold 51.57 24.45 34 9829 12939 42598533
Aggression 51.30 24.45 57 9806 44106 42567366
Colitis microscopic 50.43 24.45 21 9842 3112 42608360
Cogwheel rigidity 50.21 24.45 18 9845 1783 42609689
Stoma site erythema 47.67 24.45 15 9848 995 42610477
Stereotypy 46.05 24.45 14 9849 828 42610644
Obsessive-compulsive personality disorder 45.78 24.45 10 9853 154 42611318
Hyperkinesia 43.95 24.45 17 9846 2081 42609391
Delirium 43.35 24.45 57 9806 52462 42559010
Dementia 42.07 24.45 33 9830 16447 42595025
Hyporesponsive to stimuli 41.41 24.45 15 9848 1531 42609941
Akinesia 41.25 24.45 17 9846 2455 42609017
Marasmus 40.97 24.45 13 9850 886 42610586
Constipation 40.74 24.45 105 9758 162186 42449286
Mobility decreased 40.02 24.45 45 9818 35261 42576211
Micturition urgency 39.73 24.45 28 9835 11870 42599602
Dysphagia 38.44 24.45 64 9799 72655 42538817
Anticholinergic syndrome 37.33 24.45 14 9849 1575 42609897
Supine hypertension 37.30 24.45 10 9853 375 42611097
Psychotic disorder 36.17 24.45 39 9824 29169 42582303
Oesophageal achalasia 35.67 24.45 10 9853 444 42611028
Rapid eye movement sleep behaviour disorder 34.42 24.45 9 9854 306 42611166
Therapeutic product effect variable 34.36 24.45 16 9847 3093 42608379
Paraphilia 33.01 24.45 7 9856 93 42611379
Fracture 31.63 24.45 21 9842 8082 42603390
Impulsive behaviour 31.61 24.45 14 9849 2411 42609061
Autonomic nervous system imbalance 31.26 24.45 15 9848 3101 42608371
Restlessness 30.98 24.45 36 9827 29213 42582259
Neutropenia 30.12 24.45 5 9858 199426 42412046
Neuroleptic malignant syndrome 28.94 24.45 30 9833 21442 42590030
Blood lactic acid 28.92 24.45 8 9855 338 42611134
Hyperthermia 27.48 24.45 23 9840 12551 42598921
Reduced facial expression 27.14 24.45 11 9852 1522 42609950
Disturbance in attention 27.12 24.45 34 9829 29832 42581640
Mesenteric artery thrombosis 26.90 24.45 9 9854 725 42610747
Dizziness 26.53 24.45 121 9742 249133 42362339
Device issue 26.05 24.45 23 9840 13486 42597986
Parkinson's disease 25.18 24.45 10 9853 1312 42610160
Dementia with Lewy bodies 25.18 24.45 9 9854 884 42610588
Micturition disorder 25.06 24.45 12 9851 2468 42609004
Sleep attacks 24.99 24.45 6 9857 143 42611329
Sleep disorder 24.96 24.45 42 9821 48053 42563419
Binge eating 24.72 24.45 6 9857 150 42611322
Frustration tolerance decreased 24.67 24.45 13 9850 3273 42608199
Thunderclap headache 24.49 24.45 6 9857 156 42611316

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 645.36 21.09 290 12946 101142 110474921
Dyskinesia 556.71 21.09 215 13021 51231 110524832
Hallucination, visual 412.25 21.09 161 13075 39444 110536619
On and off phenomenon 357.67 21.09 87 13149 4337 110571726
Impulse-control disorder 304.74 21.09 67 13169 2127 110573936
Fall 272.73 21.09 347 12889 603135 109972928
Orthostatic hypotension 239.30 21.09 129 13107 66120 110509943
Freezing phenomenon 235.03 21.09 56 13180 2553 110573510
Serotonin syndrome 230.04 21.09 121 13115 59032 110517031
Hypersexuality 197.60 21.09 46 13190 1894 110574169
Gambling disorder 192.03 21.09 46 13190 2145 110573918
Delusion 157.27 21.09 70 13166 23685 110552378
Dopamine dysregulation syndrome 149.84 21.09 30 13206 597 110575466
Tremor 148.42 21.09 150 13086 202082 110373981
Bradykinesia 137.88 21.09 51 13185 10737 110565326
Muscle rigidity 137.57 21.09 64 13172 23967 110552096
Dystonia 115.30 21.09 58 13178 25747 110550316
Stoma site discharge 109.77 21.09 31 13205 2764 110573299
Confusional state 108.59 21.09 198 13038 468482 110107581
Akinesia 101.46 21.09 31 13205 3636 110572427
Sudden onset of sleep 100.41 21.09 22 13214 686 110575377
Drug interaction 89.95 21.09 190 13046 499993 110076070
Agitation 88.64 21.09 87 13149 112964 110463099
Resting tremor 85.66 21.09 23 13213 1700 110574363
Colitis microscopic 80.79 21.09 37 13199 13357 110562706
Dementia 75.19 21.09 47 13189 31626 110544437
Abnormal behaviour 70.90 21.09 49 13187 38990 110537073
Balance disorder 70.36 21.09 78 13158 116482 110459581
Compulsive shopping 69.78 21.09 17 13219 851 110575212
Jealous delusion 68.76 21.09 15 13221 458 110575605
Nocturia 63.84 21.09 34 13202 16956 110559107
Aggression 60.81 21.09 53 13183 59157 110516906
Device dislocation 60.43 21.09 41 13195 31663 110544400
Hyperkinesia 59.61 21.09 20 13216 3164 110572899
Somnolence 59.26 21.09 118 13118 297331 110278732
Stoma site erythema 59.00 21.09 18 13218 2099 110573964
Supine hypertension 58.35 21.09 13 13223 438 110575625
Autonomic nervous system imbalance 58.30 21.09 23 13213 5757 110570306
Fracture 56.87 21.09 36 13200 24752 110551311
Psychotic disorder 55.15 21.09 47 13189 50890 110525173
Syncope 55.12 21.09 92 13144 202444 110373619
Anxiety 55.00 21.09 125 13111 344953 110231110
Marasmus 54.13 21.09 16 13220 1675 110574388
Rapid eye movement sleep behaviour disorder 53.85 21.09 13 13223 626 110575437
Dysphagia 53.25 21.09 78 13158 153522 110422541
Speech disorder 53.18 21.09 50 13186 61519 110514544
Cogwheel rigidity 52.89 21.09 19 13217 3679 110572384
Gait disturbance 52.59 21.09 108 13128 278100 110297963
Stereotypy 52.56 21.09 14 13222 1003 110575060
Pleurothotonus 52 21.09 17 13219 2481 110573582
Death 49.13 21.09 189 13047 698680 109877383
Obsessive-compulsive personality disorder 47.79 21.09 9 13227 128 110575935
Delirium 47.42 21.09 69 13167 134956 110441107
Dementia with Lewy bodies 47.25 21.09 13 13223 1053 110575010
Hyperthermia 46.58 21.09 30 13206 21242 110554821
Neuroleptic malignant syndrome 46.53 21.09 36 13200 34023 110542040
Disturbance in attention 45.40 21.09 46 13190 61949 110514114
Impulsive behaviour 43.56 21.09 16 13220 3299 110572764
Pneumonia aspiration 43.31 21.09 51 13185 81182 110494881
Psychomotor hyperactivity 42.93 21.09 28 13208 20249 110555814
Cognitive disorder 41.86 21.09 52 13184 87459 110488604
Sleep talking 40.60 21.09 12 13224 1256 110574807
Stoma site infection 40.56 21.09 13 13223 1782 110574281
Compulsive hoarding 39.91 21.09 7 13229 65 110575998
Choking 39.88 21.09 24 13212 15086 110560977
Stoma site hypergranulation 39.37 21.09 10 13226 594 110575469
Disorientation 38.73 21.09 45 13191 70626 110505437
Paraphilia 38.67 21.09 7 13229 79 110575984
Abnormal dreams 38.20 21.09 22 13214 12758 110563305
Altered state of consciousness 37.25 21.09 40 13196 57586 110518477
Loss of consciousness 35.65 21.09 75 13161 196231 110379832
Mesenteric artery thrombosis 34.85 21.09 10 13226 943 110575120
Oesophageal achalasia 34.17 21.09 10 13226 1011 110575052
Anticholinergic syndrome 32.83 21.09 14 13222 4266 110571797
Compulsions 32.61 21.09 8 13228 412 110575651
Micturition urgency 32.17 21.09 23 13213 19297 110556766
Off label use 32.09 21.09 84 13152 1500101 109075962
Sleep attacks 31.77 21.09 7 13229 224 110575839
Presyncope 31.71 21.09 34 13202 48853 110527210
Device issue 31.66 21.09 29 13207 34506 110541557
Therapeutic product effect variable 31.63 21.09 12 13224 2706 110573357
Blood lactic acid 31.58 21.09 8 13228 470 110575593
Swelling 31.15 21.09 3 13233 351038 110225025
Restlessness 31.12 21.09 36 13200 56223 110519840
Autonomic neuropathy 29.85 21.09 11 13225 2289 110573774
Therapeutic response shortened 29.40 21.09 26 13210 29557 110546506
Parkinsonian gait 29.39 21.09 9 13227 1063 110575000
Hip fracture 29.30 21.09 28 13208 35123 110540940
Middle insomnia 28.72 21.09 22 13214 20480 110555583
Obsessive-compulsive disorder 28.64 21.09 15 13221 7226 110568837
Constipation 28.62 21.09 101 13135 357685 110218378
Poor quality sleep 28.55 21.09 25 13211 28052 110548011
Serum serotonin increased 28.27 21.09 7 13229 375 110575688
Reduced facial expression 28.20 21.09 12 13224 3639 110572424
Insomnia 28.16 21.09 101 13135 360489 110215574
Coronary artery dissection 28.04 21.09 9 13227 1239 110574824
Device connection issue 27.86 21.09 9 13227 1265 110574798
Hepatic enzyme increased 27.81 21.09 3 13233 320889 110255174
Drug hypersensitivity 27.49 21.09 10 13226 454080 110121983
Drug withdrawal syndrome 27.43 21.09 28 13208 38026 110538037
Diarrhoea 27.34 21.09 60 13176 1139445 109436618
Parkinsonism 27.19 21.09 22 13214 22165 110553898
Hyperpyrexia 27.12 21.09 15 13221 8054 110568009
Drooling 26.01 21.09 14 13222 7125 110568938
Panic attack 25.94 21.09 24 13212 28916 110547147
Gastrointestinal motility disorder 25.76 21.09 14 13222 7262 110568801
Micturition disorder 25.30 21.09 12 13224 4686 110571377
Urticaria 25.19 21.09 4 13232 318853 110257210
Paranoia 24.94 21.09 21 13215 22353 110553710
Joint swelling 24.77 21.09 11 13225 442834 110133229
Hyperhidrosis 24.58 21.09 63 13173 187235 110388828
Rash 24.30 21.09 38 13198 820926 109755137
Hypersensitivity 24.28 21.09 9 13227 403989 110172074
Stoma site pain 24.05 21.09 9 13227 1954 110574109
Alopecia 23.89 21.09 7 13229 364746 110211317
Pruritus 23.53 21.09 21 13215 581539 109994524
Dizziness postural 23.42 21.09 17 13219 14592 110561471
Nightmare 23.41 21.09 26 13210 38837 110537226
Dysstasia 23.28 21.09 24 13212 32962 110543101
Blood pressure fluctuation 23.07 21.09 36 13200 74788 110501275
Treatment failure 23.01 21.09 3 13233 277231 110298832
Depressed mood 22.69 21.09 32 13204 60777 110515286
Stoma site haemorrhage 22.30 21.09 9 13227 2389 110573674
Product use in unapproved indication 22.21 21.09 13 13223 447364 110128699
Intermittent claudication 21.62 21.09 10 13226 3691 110572372
Psychotic symptom 21.20 21.09 10 13226 3857 110572206

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BD02 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Monoamine oxidase B inhibitors
FDA MoA N0000000184 Monoamine Oxidase Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D008996 Monoamine Oxidase Inhibitors
MeSH PA D018696 Neuroprotective Agents
MeSH PA D020011 Protective Agents
FDA EPC N0000175744 Monoamine Oxidase Inhibitor
CHEBI has role CHEBI:38623 EC 1.4.3.4 (monoamine oxidase) inhibitor
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:63726 neuroprotective agent

Related Drugs by ATC class:

N04BD Monoamine oxidase B inhibitors 2 drugs
safinamideselegiline

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Parkinson's disease indication 49049000 DOID:14330
Dyskinesia contraindication 9748009
Bipolar disorder contraindication 13746004 DOID:3312
Orthostatic hypotension contraindication 28651003
Hypertensive disorder contraindication 38341003 DOID:10763
Epilepsy contraindication 84757009 DOID:1826
Disease of liver contraindication 235856003 DOID:409
Pheochromocytoma contraindication 302835009
Malignant melanoma contraindication 372244006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.54 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.5MG BASE AZILECT TEVA N021641 May 16, 2006 RX TABLET ORAL 7815942 Aug. 27, 2027 TREATMENT OF PARKINSONS DISEASE
EQ 1MG BASE AZILECT TEVA N021641 May 16, 2006 RX TABLET ORAL 7815942 Aug. 27, 2027 TREATMENT OF PARKINSONS DISEASE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Amine oxidase [flavin-containing] B Enzyme INHIBITOR Ki 6.15 CHEMBL CHEMBL
Acetylcholinesterase Enzyme IC50 7.72 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 8.85 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 5.01 CHEMBL
Cholinesterase Enzyme IC50 5.32 CHEMBL
Amine oxidase [flavin-containing] B Enzyme IC50 8.36 CHEMBL
Amine oxidase [flavin-containing] A Enzyme IC50 6.39 CHEMBL

External reference:

IDSource
4025261 VUID
N0000179514 NUI
D02562 KEGG_DRUG
136236-50-5 SECONDARY_CAS_RN
161735-79-1 SECONDARY_CAS_RN
4025261 VANDF
4025262 VANDF
C0525678 UMLSCUI
CHEBI:63620 CHEBI
RAU PDB_CHEM_ID
CHEMBL887 ChEMBL_ID
DB01367 DRUGBANK_ID
CHEMBL1201142 ChEMBL_ID
CHEMBL1235738 ChEMBL_ID
3052776 PUBCHEM_CID
7151 INN_ID
C031967 MESH_SUPPLEMENTAL_RECORD_UI
6641 IUPHAR_LIGAND_ID
003N66TS6T UNII
134748 RXNORM
162358 MMSL
20417 MMSL
70623 MMSL
d05612 MMSL
010775 NDDF
010776 NDDF
418734001 SNOMEDCT_US
419010007 SNOMEDCT_US
734664007 SNOMEDCT_US
003N66TS6T INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 0093-3060 TABLET 0.50 mg ORAL NDA authorized generic 29 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 0093-3061 TABLET 1 mg ORAL NDA authorized generic 29 sections
RASAGILINE HUMAN PRESCRIPTION DRUG LABEL 1 13668-446 TABLET 1 mg ORAL ANDA 17 sections
RASAGILINE HUMAN PRESCRIPTION DRUG LABEL 1 13668-447 TABLET 0.50 mg ORAL ANDA 17 sections
Rasagiline Human Prescription Drug Label 1 16714-770 TABLET 0.50 mg ORAL ANDA 29 sections
Rasagiline Human Prescription Drug Label 1 16714-771 TABLET 1 mg ORAL ANDA 29 sections
Rasagiline mesylate Human Prescription Drug Label 1 23155-746 TABLET 0.50 mg ORAL ANDA 29 sections
Rasagiline mesylate Human Prescription Drug Label 1 23155-747 TABLET 1 mg ORAL ANDA 29 sections
Rasagiline Human Prescription Drug Label 1 33342-308 TABLET 0.50 mg ORAL ANDA 29 sections
Rasagiline Human Prescription Drug Label 1 33342-309 TABLET 1 mg ORAL ANDA 29 sections
RASAGILINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-220 TABLET 0.50 mg ORAL ANDA 29 sections
RASAGILINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-221 TABLET 1 mg ORAL ANDA 29 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 47781-683 TABLET 0.50 mg ORAL ANDA 27 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 47781-683 TABLET 0.50 mg ORAL ANDA 27 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 47781-690 TABLET 1 mg ORAL ANDA 27 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 47781-690 TABLET 1 mg ORAL ANDA 27 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 51407-008 TABLET 0.50 mg ORAL ANDA 30 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 51407-009 TABLET 1 mg ORAL ANDA 30 sections
Azilect HUMAN PRESCRIPTION DRUG LABEL 1 54868-6206 TABLET 1 mg ORAL NDA 30 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 62135-676 TABLET 0.50 mg ORAL ANDA 18 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 62135-677 TABLET 1 mg ORAL ANDA 18 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 64980-711 TABLET 0.50 mg ORAL ANDA 30 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 64980-712 TABLET 1 mg ORAL ANDA 30 sections
Rasagiline Human Prescription Drug Label 1 67877-259 TABLET 0.50 mg ORAL ANDA 29 sections
Rasagiline Human Prescription Drug Label 1 67877-260 TABLET 1 mg ORAL ANDA 29 sections
Azilect HUMAN PRESCRIPTION DRUG LABEL 1 68546-142 TABLET 0.50 mg ORAL NDA 30 sections
Azilect HUMAN PRESCRIPTION DRUG LABEL 1 68546-229 TABLET 1 mg ORAL NDA 30 sections
Rasagiline HUMAN PRESCRIPTION DRUG LABEL 1 70518-4683 TABLET 0.50 mg ORAL ANDA 29 sections
Rasagiline mesylate Human Prescription Drug Label 1 71921-407 TABLET 0.50 mg ORAL ANDA 29 sections
Rasagiline mesylate Human Prescription Drug Label 1 71921-408 TABLET 1 mg ORAL ANDA 29 sections